Press Releases
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
Abbott announced that the U.S. FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in...
Press Releases
Bora strengthens business development team to support US growth
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release oral solids and packaging, has announced the appointment of Mr. Lonnie Barish, MBA as Vice President of Business Development and Marketing.
Adding more...
Drug Research
Destroying DNA to Save the Genome – Study Offers New Insights into Sepsis and its Treatment
Sepsis is a life-threatening condition that kills millions annually; it is poorly understood and has no specific treatment. Now, researchers from Tata Memorial Centre, India, led by Prof. Dr Indraneel Mittra, have uncovered an important molecular mechanism underlying different...
Drug Research
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment
C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. In early March, the API was listed for...
Press Releases
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the U.S. FDA has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA)...
Press Releases
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
Vir Biotechnology, Inc announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.
“We are pleased with the rapidity of our progress and excited to move two development candidates into...
Press Releases
Positive update on the development of new XF-platform drug formulations
Destiny Pharma , a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces the completion of the initial phase of its project with MedPharm...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.